Valuation: Nexstim Oyj

Market Cap 78.33M 89.83M 73.77M 67.18M 126M 8.61B 126M 883M 341M 4.38B 337M 330M 14.15B P/E 2026 *
97x
P/E 2027 * 42.2x
Enterprise Value 76.68M 87.94M 72.22M 65.77M 123M 8.43B 123M 865M 333M 4.29B 330M 323M 13.85B EV / Sales 2026 *
5.77x
EV / Sales 2027 * 4.86x
Free-Float
59.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 89.83M
+1.12%+7.36%+37.36%+31.33% 244B
+1.90%+6.19%+11.67%-13.54% 152B
+2.12%+6.27%-8.45%+41.25% 142B
+0.88%-2.95%-55.31%-18.99% 63.36B
+0.09%+3.30%+18.72%+25.88% 50.92B
+0.53%-2.62%-19.47%-16.99% 48.47B
+3.50%+10.31%+28.20%+47.58% 45.66B
+0.54%+3.39%+40.90%+57.67% 41.65B
-0.33%+14.70%+132.43%+79.12% 36.06B
Average +0.28%+4.83%+20.67%+25.92% 91.48B
Weighted average by Cap. +1.20%+5.46%+16.94%+22.04%

Financials

2026 *2027 *
Net sales 13.3M 15.25M 12.53M 11.41M 21.39M 1.46B 21.42M 150M 57.82M 744M 57.3M 56.03M 2.4B 15.55M 17.83M 14.65M 13.34M 25.01M 1.71B 25.04M 175M 67.6M 870M 66.99M 65.51M 2.81B
Net income 750K 860K 706K 643K 1.21M 82.41M 1.21M 8.46M 3.26M 41.98M 3.23M 3.16M 135M 1.85M 2.12M 1.74M 1.59M 2.98M 203M 2.98M 20.87M 8.04M 104M 7.97M 7.79M 334M
Net Debt -1.65M -1.89M -1.55M -1.42M -2.65M -181M -2.66M -18.61M -7.17M -92.35M -7.11M -6.95M -298M -2.8M -3.21M -2.64M -2.4M -4.5M -308M -4.51M -31.58M -12.17M -157M -12.06M -11.8M -506M
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!